Primary outcome 3: Adverse events · people (all patch‐tested) with hand eczema > 6 months that had cleared upon daily treatment for a maximum of 9 weeks with mometasone…
Corticosteroid creams/ointments: mometasone furoate cream 3 times/week showed no clear difference in primary: adverse events compared with 2 times/week (low certainty).
1 finding from 1 review
Number of participants with any adverse event (primary tolerability outcome) · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…
Oral immunosuppressants: oral cyclosporin showed no clear difference in primary: adverse events ‐ at least 1 adverse event compared with topical betamethasone dipropionate (moderate certainty).
1 finding from 1 review
Adverse events · bullous pemphigoid
1 finding from 1 review
Adverse events · chronic pruritus of unknown origin
It is very uncertain whether serlopitant 0.25 mg changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
Adverse events · chronic pruritus of unknown origin
It is very uncertain whether serlopitant 5 mg changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
Adverse events · chronic pruritus of unknown origin
It is very uncertain whether serlopitant 1 mg changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
Adverse events · infantile seborrhoeic dermatitis (including cradle cap)
1 finding from 1 review
Adverse events · infantile seborrhoeic dermatitis (including cradle cap)
1 finding from 1 review
Adverse events · infantile seborrhoeic dermatitis (including cradle cap)
1 finding from 1 review
Adverse events · women with FPHL
Minoxidil 2% showed no clear difference in adverse events compared with minoxidil 5% (low certainty).
1 finding from 1 review
Adverse events · women with FPHL
Finasteride showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Adverse events · women with FPHL
1 finding from 1 review
Adverse events · women with FPHL
Minoxidil showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral hydroxychloroquine showed no clear difference in adverse events: minor compared with placebo (moderate certainty).
1 finding from 1 review
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral dehydroepiandrosterone probably leads to higher adverse events: minor compared with placebo (moderate certainty).
1 finding from 1 review
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate may leads to higher adverse events: minor compared with oral chloroquine (low certainty).
1 finding from 1 review
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate showed no clear difference in adverse events: minor compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral hydroxychloroquine showed no clear difference in adverse events: severe compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral dehydroepiandrosterone showed no clear difference in adverse events: severe compared with placebo (moderate certainty).
1 finding from 1 review